Taithera, Inc.

Revolutionary bone targeted drug delivery platform for the treatment of musculoskeletal disorders including bone cancer, osteoporosis, & fractures.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location New York, NY, US
  • Currency USD
  • Founded March 2016
  • Employees 2
  • Incorporation Type C-corp
  • Website taithera.com

Company Summary

Taithera is a revolutionary bone targeted drug delivery and controlled release technology for the treatment of musculoskeletal conditions.

Taithera's highly targeted precision medicine platform is changing the way the world treats bone cancer and osteoporosis, and is helping to heal fractures than was ever possible.

Taithera is the fastest way to healthy bones.

Team

  • Seth Harlem
    Co-founder & CEO

    Prior to co-founding Taithera, Seth co-founded a data analytics and marketing technology company. Seth also serves as an advisor to a healthcare startup. Seth helped build a team, raise venture capital, and launch product at Zipmark, Inc., a venture backed financial technology company. Seth also established the U.S. presence of Hundsun Technologies, China's largest financial technology company.

    MBA, Columbia University
    BA, Trinity College.

  • Mo Chen
    Co-founder & Chief Science Officer

    Prior to Taithera, Dr. Chen was a Research Scientist at the Center for Craniofacial Regeneration at Columbia University. Chen has been published more than 40 times including in the Journal of Bone and Mineral Research, and Journal of Cell Science. Chen holds 5 patents, and has received 5 NIH grants.

    PhD in Genetics and Development; MS in Genetics from the University of Rochester
    MS and BS in Biochemistry from Jilin University
    MBA from Columbia

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free